Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.42 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474584 | 0.86 | HSD11B1 (0.43) | HSD11B1APLNRCES2CES1HDAC8 | |
| SCHEMBL21883492 | 0.83 | APLNR (0.38) | HSD11B1APLNR | |
| SCHEMBL19933348 | 0.82 | HSD11B1 (0.39) | HSD11B1APLNRCES2CES1HDAC8 | |
| SCHEMBL23253594 | 0.78 | APLNR (0.40) | HSD11B1APLNRCES2CES1TSHR | |
| SCHEMBL2154593 | 0.77 | CES2 (0.38) | HSD11B1CES2CES1HDAC8HDAC6 | |
| SCHEMBL19121536 | 0.77 | HSD11B1 (0.35) | HSD11B1CES2CES1HPGDTSHR | |
| SCHEMBL8933185 | 0.75 | APLNR (0.44) | HSD11B1APLNRCES2CES1 | |
| Ethane SCHEMBL2153406 | 0.74 | CES2 (0.52) | HSD11B1CES2CES1HDAC8HDAC6 | |
| SCHEMBL11285851 | 0.74 | — | — | |
| Ethane SCHEMBL27878529 | 0.74 | CES2 (0.52) | HSD11B1CES2CES1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | HSD11B1 332/4885APLNR 4658/4885CES2 3480/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HSD11B1 332/4885APLNR 4658/4885CES2 3480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.